Weekly Trademark Review – Issued Oct 4, 2011
This article was originally published in The Tan Sheet
You may also be interested in...
Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.
With the meetings available on television, access can be assured for just about everyone, and the US FDA can avoid another gut punch to its credibility.
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.